ArticleFinance research letters2022
COVID-19 vaccines and global stock markets.
Article in Finance research letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- COVID-19 vaccination and household savings: An economic recovery channel.Finance research letters · 2023Article
- How reactive is investment in US green bonds and ESG-eligible stocks in times of crisis? Exploring the COVID-19 crisis.Finance research letters · 2023Article
- Does US full vaccination against COVID-19 immunize correspondingly S&P500 index: Evidence from the NARDL approach.Heliyon · 2023Article
- Portfolio diversification during the COVID-19 pandemic: Do vaccinations matter?Journal of financial stability · 2023Article
- Comparative evidence on the impact of the COVID-19 outbreak and vaccine discovery on the global transportation industry.Transportation research interdisciplinary perspectives · 2023Article
- Airline stock markets reaction to the COVID-19 outbreak and vaccines: An event study.Journal of air transport management · 2022Article
- The impact of COVID-19 vaccination on stock market: is there any difference between developed and developing countries?Heliyon · 2022Article
- Winners and losers from Pfizer and Biontech's vaccine announcement: Evidence from S&P 500 (Sub)sector indices.PloS one · 2022Article
- The stock market reaction to COVID-19 vaccination in ASEAN.F1000Research · 2022Article
- Immunizing markets against the pandemic: COVID-19 vaccinations and stock volatility around the world.International review of financial analysis · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global stock markets react positively when different phases of human clinical trials on COVID-19 vaccines begin. The average abnormal stock return on the first day of the trials is both statistically and economically significant at 8.08 basis points. The increase in the average abnormal stock return is threefold higher for leading vaccine candidates. The positive reaction is more pronounced upon the start of phase III trials, and it is also stronger for vaccine candidates developed by the U.S. and China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.